On September 16, 2015, Swiss pharmaceutical company Roche announced that ocrelizumab, a drug originally designed to treat rheumatoid arthritis that saw its development stopped due to an association with infections, could potentially treat relapsing-remitting multiple sclerosis (RRMS) as well as primary progressive MS (PPMS) with minimal sides effects compared to other commercially available drugs. Full details on the clinical trial results assessing the efficacy and safety of ocrelizumab will be disclosed on October 7-10 at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.
additional information found here
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews